been included as part of pre-transplant conditioning regimens among allosensitized patients awaiting renal transplantation. Post-transplant, rituximab has been used to prevent and/or treat allograft rejection (both acute and chronic) and to facilitate ABO mismatched kidney transplants (1) . When used in these clinical situations, the presence of rituximab in patient sera may interfere with transplant immunologic monitoring.
Preformed alloantibodies (predominantly HLA specific) in a sensitized individual react with antigens expressed on the vascular endothelial cells of organ allografts. Such antibodies can activate the classical complement pathway resulting in rapid necrosis of the transplanted tissue. Prior sensitization of recipients to donor alloantigens occurs by pathways including blood transfusion, pregnancies and previous allografts. The performance of a crossmatch immediately before the transplant is still performed as a measure to prevent hyperacute or accelerated allograft rejection. As well, crossmatch monitoring may be performed after transplant. Thus, the persistence of rituximab in patient serum/plasma can negatively impact crossmatch and alloantibody analysis. Since rituximab is cytotoxic in the presence of complement, sera that contain rituximab may result in a positive cytotoxic crossmatch assay, a result that would be mistakenly attributed to donor directed HLA alloantibodies. Additionally, the human portion of the chimeric monoclonal antibody provides a target for the anti-human Ig fluorochromes, thereby resulting in a positive flow cytometric crossmatch. Clearly, it is challenging to perform transplant crossmatch analysis when exogenous anti-lymphocyte antibodies such as rituximab are present. To overcome this issue, several methods can be applied. One method uses pronase, a proteolytic enzyme that removes CD20 from the surface of B cells by Fc receptor digestion (CD20 is a member of the Fc receptor family of proteins) (2) . After CD20 is removed, rituximab typically no longer binds B cells, thereby making it possible to clearly detect class I and II Major Histocompatibility (MHC) antibodies using B cell targets. An alternative to Fc receptor digestion is to adsorb rituximab from the serum onto microparticles coated with polyclonal anti-mouse antibody (3).
Herein, we modify the conjugated bead assay described above. Instead of an anti-mouse antibody, a small fragment of the extracellular CD20 structure (residues 163 -187) that We suggest that the method described in this paper is a viable option to eliminate the complications of interpreting crossmatch results in those patients who have received rituximab therapy. This method may be modified for use of elimination of other interfering chimeric antibodies as many more of these products are being used clinically. 
